Management of SLE in Pregnancy: Preconception, Antenatal, and Postpartum
All women with SLE planning pregnancy must achieve disease remission for at least 6 months before conception, continue hydroxychloroquine throughout pregnancy, and receive low-dose aspirin starting in the first trimester. 1, 2
Preconception Phase (Prenatal Planning)
Risk Stratification and Timing
The most critical determinant of pregnancy success is disease activity at conception—active SLE, especially active nephritis, dramatically increases maternal and fetal complications 2. Pregnancy should be delayed until:
- Disease inactive for ≥6 months (ideally 12 months if history of lupus nephritis)
- No major organ damage present
- Patient on pregnancy-compatible medications
Essential Preconception Testing
Perform once before or early in pregnancy (do not repeat during pregnancy) 1:
- Antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, anti-β2GPI
- Anti-Ro/SSA and anti-La/SSB antibodies (for neonatal lupus/congenital heart block risk)
- Renal function: urinalysis, protein:creatinine ratio, serum creatinine
- Complement levels (C3, C4) and anti-dsDNA as baseline
- Complete blood count
Medication Optimization
- Hydroxychloroquine: Continue if already taking; start if not (unless contraindicated)—reduces flare risk and improves pregnancy outcomes
SAFE during pregnancy 2:
- Azathioprine
- Tacrolimus
- Cyclosporine A
- Oral glucocorticoids (lowest effective dose)
MUST DISCONTINUE before conception 2:
- Mycophenolate mofetil/mycophenolic acid (stop 3-6 months before)
- Methotrexate (stop 3 months before)
- Cyclophosphamide
- Leflunomide
Biologics: Rituximab, belimumab, abatacept can continue until conception 3
Fertility Preservation
If alkylating agents (cyclophosphamide) needed before pregnancy, use GnRH analogues for ovarian protection 2
Antenatal Phase (During Pregnancy)
Medication Management
Universal treatment for all SLE pregnancies 1, 2:
- Hydroxychloroquine: Continue throughout pregnancy
- Low-dose aspirin 81-100 mg daily: Start by end of first trimester (ideally preconceptionally), continue until delivery—reduces preeclampsia risk
Additional therapy based on risk 2:
- Lupus nephritis or positive aPL: Add prophylactic heparin (LMWH preferred over unfractionated)
- Definite APS: Combination low-dose aspirin + therapeutic-dose heparin (mandatory)
For disease flares during pregnancy 2:
- Mild-moderate: Increase glucocorticoids, optimize hydroxychloroquine
- Severe: IV methylprednisolone pulse therapy, IVIG, or plasmapheresis
- Continue azathioprine, tacrolimus, or cyclosporine as needed
Monitoring Schedule
Maternal monitoring—at least once per trimester (more frequently if high-risk) 1, 2:
- Clinical assessment for disease activity
- Blood pressure (every visit)
- Complete blood count
- Urinalysis and protein:creatinine ratio
- Complement levels (C3, C4) and anti-dsDNA
- Renal function tests
Fetal monitoring 2:
- Third trimester focus: Doppler ultrasonography and fetal biometry to detect placental insufficiency and fetal growth restriction
- If anti-Ro/SSA or anti-La/SSB positive: Fetal echocardiography if suspected dysrhythmia or myocarditis (though routine intensive monitoring between 16-26 weeks has unclear cost-effectiveness given low 0.7-2% risk) 2
Common Pitfalls
- Distinguishing preeclampsia from lupus nephritis flare: Both present with proteinuria and hypertension—use complement levels (low in active lupus, normal in preeclampsia), anti-dsDNA (elevated in lupus flare), and platelet count patterns
- Physiological pregnancy changes mimicking lupus: Mild anemia, increased ESR, and trace proteinuria are normal in pregnancy
- Stopping hydroxychloroquine: Never discontinue—this is the single most important medication for pregnancy success
Postpartum Phase (Postnatal)
Immediate Postpartum Period
Highest flare risk occurs in first 3-6 months postpartum 4, 5:
- Resume or intensify monitoring frequency (monthly for first 3 months)
- Continue hydroxychloroquine
- Maintain low-dose aspirin if indicated for thrombosis risk
- Monitor for signs of flare: new rash, arthritis, serositis, cytopenias, rising anti-dsDNA, falling complements
Medication Adjustments
Safe during lactation 3:
- Hydroxychloroquine (continue)
- Azathioprine
- Tacrolimus
- Cyclosporine
- Prednisone (minimize dose)
- Low-dose aspirin
Can resume after delivery (avoid during breastfeeding or use with caution):
- Mycophenolate: Resume if needed for disease control (avoid breastfeeding)
- Biologics (rituximab, belimumab, abatacept): Can resume, compatible with lactation per limited data
Contraception Counseling
Provide immediately postpartum 2:
- IUD (copper or levonorgestrel): Safe for all SLE patients regardless of aPL status
- Combined hormonal contraceptives: Only if stable/inactive disease AND negative aPL
- Progestin-only methods: Consider if positive aPL, but weigh thrombosis risk carefully
Neonatal Monitoring
If mother anti-Ro/SSA or anti-La/SSB positive 2:
- Monitor neonate for neonatal lupus (rash, cytopenias, hepatitis)—typically resolves by 6 months
- Congenital heart block is permanent if present—requires pacemaker
Supplementation
Continue throughout postpartum 2:
- Calcium and vitamin D (especially if on glucocorticoids or received heparin)
- Folic acid if planning another pregnancy
Key Risk Factors for Adverse Outcomes
Highest risk scenarios 2:
- Active disease at conception (especially active nephritis)
- History of lupus nephritis
- Positive antiphospholipid antibodies or definite APS
- Discontinuation of hydroxychloroquine
- High-dose glucocorticoid requirement (>20 mg/day prednisone)
The evidence strongly supports that optimal outcomes require: disease quiescence at conception, continuation of hydroxychloroquine, addition of low-dose aspirin, and intensive multidisciplinary monitoring throughout pregnancy and postpartum 1, 2.